MX2020006071A - Nuevas formas solidas de cannabidiol y sus usos. - Google Patents

Nuevas formas solidas de cannabidiol y sus usos.

Info

Publication number
MX2020006071A
MX2020006071A MX2020006071A MX2020006071A MX2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A
Authority
MX
Mexico
Prior art keywords
cannabidiol
solid forms
new solid
cocrystals
proline
Prior art date
Application number
MX2020006071A
Other languages
English (en)
Inventor
Patricia Andres
Mark Andres
R Martin Emanuele
Tanise Shattock-Gordon
Tabitha Williford
Original Assignee
Artelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artelo Biosciences Inc filed Critical Artelo Biosciences Inc
Publication of MX2020006071A publication Critical patent/MX2020006071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se divulgan cocristales de cannabidiol y un coformador que contiene anillos de 5-6 miembros compuestos de átomos de carbono y nitrógeno, en donde los anillos de 5-6 miembros pueden ser insaturados o saturados y los anillos contienen 1 a 2 átomos de nitrógeno. También se divulgan en la presente los cocristales de cannabidiol y un coformador seleccionado de L-prolina, D-prolina, tetrametilpirazina y 4,4'-dipiridilo.
MX2020006071A 2017-12-11 2018-12-10 Nuevas formas solidas de cannabidiol y sus usos. MX2020006071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597307P 2017-12-11 2017-12-11
PCT/US2018/064773 WO2019118360A1 (en) 2017-12-11 2018-12-10 New solid forms of cannabidiol and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006071A true MX2020006071A (es) 2020-10-28

Family

ID=66735157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006071A MX2020006071A (es) 2017-12-11 2018-12-10 Nuevas formas solidas de cannabidiol y sus usos.

Country Status (11)

Country Link
US (4) US20190177258A1 (es)
EP (1) EP3723752A4 (es)
JP (1) JP7429013B2 (es)
KR (1) KR20200097285A (es)
CN (1) CN111447929B (es)
AU (1) AU2018383598B2 (es)
BR (1) BR112020011625A2 (es)
CA (1) CA3085331A1 (es)
MX (1) MX2020006071A (es)
TW (1) TWI794361B (es)
WO (1) WO2019118360A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168047B2 (en) 2017-08-07 2021-11-09 Enantia, S.L. Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol
US11667612B2 (en) * 2017-10-25 2023-06-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
CN113905730A (zh) * 2018-10-31 2022-01-07 南迪亚公司 ***素共晶体的固体组合物
CA3150266A1 (en) * 2019-09-06 2021-03-11 Joanne Holland CANNABIGEROL-PROLINE CO-CRYSTALS
WO2021138610A1 (en) * 2020-01-03 2021-07-08 Purisys Llc Cocrystals of cannabinoids
US10981849B1 (en) * 2020-02-20 2021-04-20 Sci Pharmtech Inc. Method for preparing cannabinoids
US20230183202A1 (en) * 2020-05-19 2023-06-15 Ebers Tech Inc. Tetrahydrococannabinolic acid cocrystals
CN111882044B (zh) * 2020-08-05 2021-09-14 四川大学 一种基于图神经网络的共晶预测方法、深度学习框架
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177163B (zh) * 2022-01-12 2023-05-02 刘树民 一种治疗高血压的药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859674A (en) 1987-06-12 1989-08-22 Houston Biotechnology Incorporated Pyrazine in prevention and treatment of strokes
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
CA2514092C (en) 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
JP4923182B2 (ja) 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
CN101969955A (zh) 2008-01-31 2011-02-09 莫纳什大学 治疗血栓栓塞疾病的方法
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US20120202891A1 (en) 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
US20110200531A1 (en) 2009-09-14 2011-08-18 The Regents Of The University Of California Treatment and diagnosis of central nervous system disorders
EP2491933A1 (en) 2009-10-23 2012-08-29 Astellas Pharma Inc. Pharmaceutical composition for oral administration
WO2012116349A2 (en) 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
WO2013040419A1 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US9822384B2 (en) 2014-07-14 2017-11-21 Librede Inc. Production of cannabinoids in yeast
EP3253727A4 (en) 2015-02-05 2018-08-08 Colorado Can LLC Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US10399920B2 (en) * 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US11168047B2 (en) * 2017-08-07 2021-11-09 Enantia, S.L. Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol

Also Published As

Publication number Publication date
TW201927733A (zh) 2019-07-16
AU2018383598B2 (en) 2024-03-07
KR20200097285A (ko) 2020-08-18
CN111447929B (zh) 2024-05-31
AU2018383598A1 (en) 2020-06-18
WO2019118360A1 (en) 2019-06-20
US10604467B2 (en) 2020-03-31
US20190177258A1 (en) 2019-06-13
EP3723752A4 (en) 2021-10-20
EP3723752A1 (en) 2020-10-21
BR112020011625A2 (pt) 2020-11-17
JP2021505674A (ja) 2021-02-18
US20210299048A1 (en) 2021-09-30
US20230404939A1 (en) 2023-12-21
US11364202B2 (en) 2022-06-21
US20190300466A1 (en) 2019-10-03
CA3085331A1 (en) 2019-06-20
JP7429013B2 (ja) 2024-02-07
TWI794361B (zh) 2023-03-01
CN111447929A (zh) 2020-07-24

Similar Documents

Publication Publication Date Title
MX2020006071A (es) Nuevas formas solidas de cannabidiol y sus usos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MY201925A (en) Macrocyclic compounds and uses thereof
MX2018002999A (es) Composiciones de inoculante estables y metodos para producir las mismas.
MX2019002453A (es) Compuestos de tetraciclina y metodos de uso de los mismos.
WO2017176957A8 (en) Mdm2 protein degraders
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MX2015014181A (es) 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
ZA202309446B (en) Rapamycin analogs and uses thereof
TN2019000211A1 (en) Antitumoral compounds
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
UA114417C2 (uk) Інгібітори iap
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2016008638A (es) Macrociclos odorizantes sutiles y amaderados.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
MX2019004312A (es) Odorante de lirio del valle.
GEP20186893B (en) Pyrazines modulators of gpr6
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
MX2020012718A (es) Derivados de benzodiazepinas novedosos y usos de los mismos.
MX2017013278A (es) Odorante osmanthus.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).